Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase ii trial

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1415-1421

  Martins, Renato G ^a   Parvathaneni, Upendra ^a   Bauman, Julie E ^d   Sharma, Anand K ^e   Raez, Luis E ^f   Papagikos, Michael A ^g   Yunus, Furhan ⁱ   Kurland, Brenda F ^b   Eaton, Keith D ^a   Liao, Jay J ^a   Mendez, Eduardo ^a   Futran, Neal ^a   Wang, David X ^c   Chai, Xiaoyu ^b   Wallace, Sarah G ^a   Austin, Melissa ^a   Schmidt, Rodney ^a   Hayes, D Neil ^h  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Multicare Health System   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g Radiation Oncology   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN P16;

ADVANCED CANCER; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DISEASE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ARRHYTHMIA; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PAIN; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84876079071     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.3299     Document Type: Article

References (22)

1. Adelstein DJ, Li Y, Adams GL, et al: Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
2. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
3. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007 (Pubitemid 46954639)
4. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
5. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized, and relation between cetuximab induced rash and survival. Lancet Oncol 11:21-28, 2010
6. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109-1117, 2008 (Pubitemid 351398485)
7. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
9. Harari PM, Allen GW, Bonner JA: Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 25:4057-4065, 2007 (Pubitemid 47492950)
10. Higgins B, Kolinsky K, Smith M, et al: Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15:503-512, 2004 (Pubitemid 38736950)
11. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004 (Pubitemid 41095117)
12. Thomas F, Rochaix P, Benlyazid A, et al: Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 13:7086-7092, 2007 (Pubitemid 350276892)
13. Siu LL, Soulieres D, Chen EX, et al: Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 25:2178-2183, 2007 (Pubitemid 46954640)
14. Jang NY, Lee KW, Ahn SH, et al: Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers. BMC Cancer 12:59-65, 2012
15. Jordan RC, Lingen MW, Perez-Ordonez B, et al: Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945-954, 2012
16. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase II study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
17. López-Albaitero A, Lee SC, Morgan S, et al: Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853-1864, 2009
18. Hughes AN, O'Brien ME, Petty WJ, et al: Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220-1226, 2009
19. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinoma. J Clin Oncol 29:360s, 2011 (suppl; abstr 5500)
20. Radiation Therapy Oncology Group: RTOG 1016 protocol information: Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. http://www.rtog.org/ClinicalTrials/ ProtocolTable/StudyDetails.aspx?study=1016
21. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000 (Pubitemid 30205391)
22. Corry J, Peters L, Fisher R, et al: N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders: Results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 30:737-742, 2008 (Pubitemid 351913849)